4UHL

HUMAN STEROL 14-ALPHA DEMETHYLASE (CYP51) IN COMPLEX WITH VFV IN P1 SPACE GROUP

4UHL の概要

• エントリーDOI: 10.2210/pdb4uhl/pdb
• 関連するPDBエントリー: 4UHI
• 分子名称: STEROL 14-ALPHA DEMETHYLASE, PROTOPORPHYRIN IX CONTAINING FE, N-[(1R)-1-(3,4'-difluorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl]-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide, ... (4 entities in total)
• 機能のキーワード: cytochrome p450, cyp51, oxidoreductase, monooxygenase, sterol biosynthesis, eukaryotic membranes, cytochrome p450 fold, endoplasmic reticulum
• 由来する生物種: HOMO SAPIENS (HUMAN)
• 細胞内の位置: Endoplasmic reticulum membrane : Q16850
• タンパク質・核酸の鎖数: 8
• 化学式量合計: 422113.07

構造登録者

Hargrove, T.Y.,Wawrzak, Z.,I Lepesheva, G. (登録日: 2015-03-24, 公開日: 2016-06-15, 最終更新日: 2024-01-10)

主引用文献

Hargrove, T.Y.,Friggeri, L.,Wawrzak, Z.,Sivakumaran, S.,Yazlovitskaya, E.M.,Hiebert, S.W.,Guengerich, F.P.,Waterman, M.R.,Lepesheva, G.I.
Human Sterol 14Alpha-Demethylase (Cyp51) as a Target for Anticancer Chemotherapy: Towards Structure-Aided Drug Design.
J.Lipid Res., 57:1552-, 2016

PubMed Abstract: Rapidly multiplying cancer cells synthesize greater amounts of cholesterol to build their membranes. Cholesterol-lowering drugs (statins) are currently in clinical trials for anticancer chemotherapy. However, given at higher doses, statins cause serious side effects by inhibiting the formation of other biologically important molecules derived from mevalonate. Sterol 14α-demethylase (CYP51), which acts 10 steps downstream, is potentially a more specific drug target because this portion of the pathway is fully committed to cholesterol production. However, screening a variety of commercial and experimental inhibitors of microbial CYP51 orthologs revealed that most of them (including all clinical antifungals) weakly inhibit human CYP51 activity, even if they display high apparent spectral binding affinity. Only one relatively potent compound, (R)-N-(1-(3,4'-difluorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide (VFV), was identified. VFV has been further tested in cellular experiments and found to decrease proliferation of different cancer cell types. The crystal structures of human CYP51-VFV complexes (2.0 and 2.5 Å) both display a 2:1 inhibitor/enzyme stoichiometry, provide molecular insights regarding a broader substrate profile, faster catalysis, and weaker susceptibility of human CYP51 to inhibition, and outline directions for the development of more potent inhibitors.

PubMed: 27313059
DOI: 10.1194/JLR.M069229

実験手法

X-RAY DIFFRACTION (2.5 Å)